HIGHFDA DRUG

Breckenridge Recalls Duloxetine Capsules Over Chemical Hazard

Breckenridge Pharmaceutical, Inc. recalled 7,389 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations and the presence of N-nitroso-duloxetine impurity above FDA limits. Consumers should stop using the product immediately and contact healthcare providers for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
November 24, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
November 24, 2025
Hazard Level
HIGH
Brands
DULOXETINE, Breckenridge Pharmaceutical, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
DULOXETINE, Breckenridge Pharmaceutical, Inc.
Product type
Duloxetine Delayed-Release Capsules
Model numbers
Lot #: 240534C, Exp. Date 01/2027, 240977C, Exp. Date 04/2027.
UPC codes
51991-746, 51991-747, 51991-748, 51991-750, 51991-746-06, 51991-746-90, 51991-746-05, 51991-747-33 +6 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    November 24, 2025

  2. Reported by FDA DRUG

    December 10, 2025

  3. RecallRadar source check

    April 13, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Breckenridge Pharmaceutical, Inc. or your healthcare provider for guidance

About This Product

Duloxetine Delayed-Release Capsules are a prescription medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. Patients buy this medication to manage chronic pain and mood disorders.

Why This Is Dangerous

The presence of N-nitroso-duloxetine above FDA limits raises concerns about potential carcinogenic effects, making the product unsafe for consumption.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers are urged to stop using the product immediately to avoid potential health risks. This recall can cause inconvenience for those relying on Duloxetine for treatment.

Practical Guidance

How to identify if yours is affected

  1. Check the lot number on your capsule bottle.
  2. Verify the expiration date.
  3. Identify if your bottle matches Lot #: 240534C or 240977C.

Where to find product info

The lot number and expiration date are typically found on the label of the bottle.

What timeline to expect

Expect a timeline of 4-6 weeks for refund processing after contacting the manufacturer.

If the manufacturer is unresponsive

  • Follow up with Breckenridge Pharmaceutical, Inc. if they do not respond promptly.
  • Document all communications and consider filing a complaint with the FDA.

How to prevent similar issues

  • Look for FDA approval and certifications when purchasing medications.
  • Be cautious of product recalls and check for updates regularly.
  • Consult with healthcare providers about alternative medications.

Documentation advice

Keep receipts, correspondence, and any documentation related to the recall for your records.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recall involves Duloxetine Delayed-Release Capsules, USP, 60 mg, sold in 1000-capsule bottles. The affected lot numbers include 240534C with an expiration date of January 2027 and 240977C with an expiration date of April 2027. These products were distributed nationwide in the United States.

Key Facts

  • Manufactured by Towa Pharmaceuticals Europe, S.L.
  • Distributed by Breckenridge Pharmaceutical, Inc.
  • N-nitroso-duloxetine impurity above FDA limits
  • Stop use immediately

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Lot #: 240534C
Exp. Date 01/2027
240977C
Exp. Date 04/2027.
UPC Codes
51991-746
51991-747
51991-748
+11 more
Affected States
ALL
Report Date
December 10, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Duloxetine Capsules Recalled Over High N-Nitroso Impurity Risk

Towa Pharmaceuticals recalled 3,397 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations resulting in N-nitroso-duloxetine levels exceeding FDA limits. Consumers must stop using the product immediately.

DULOXETINE
CGMP Deviations;
Read more